DNA Methylation and Type 2 Diabetes: the Use of Mendelian Randomization to Assess Causality.

View Abstract

Purpose of Review

This review summarises recent advances in the field of epigenetics in order to understand the aetiology of type 2 diabetes (T2D).

Recent Findings

DNA methylation at a number of loci has been shown to be robustly associated with T2D, including , and . However, due to the cross-sectional nature of many epidemiological studies and predominant analysis in samples derived from blood rather than disease relevant tissues, inferring causality is difficult. We therefore outline the use of Mendelian randomisation (MR) as one method able to assess causality in epigenetic studies of T2D.

Summary

Epidemiological studies have been fruitful in identifying epigenetic markers of T2D. Triangulation of evidence including utilisation of MR is essential to delineate causal from non-causal biomarkers of disease. Understanding the causality of epigenetic markers in T2D more fully will aid prioritisation of CpG sites as early biomarkers to detect disease or in drug development to target epigenetic mechanisms in order to treat patients.

Investigators
Abbreviation
Curr Genet Med Rep
Publication Date
2019-11-15
Volume
7
Issue
4
Page Numbers
191-207
Pubmed ID
32274260
Medium
Print-Electronic
Full Title
DNA Methylation and Type 2 Diabetes: the Use of Mendelian Randomization to Assess Causality.
Authors
Juvinao-Quintero DL, Hivert MF, Sharp GC, Relton CL, Elliott HR